A randomized comparison of ferumoxytol and iron sucrose for treating iron deficiency anemia in patients with CKD.

ABSTRACT:

Background and objectives

Few randomized controlled trials have compared intravenous iron products head to head in CKD patients with iron deficiency anemia. This study compared the efficacy and safety of two intravenous iron products (ferumoxytol [Feraheme injection] and iron sucrose [Venofer]) in patients with CKD and iron deficiency anemia.

Design, setting, participants, & measurements

In this phase II, randomized, open-label, active-controlled, multicenter clinical trial, patients were randomized 1:1 to either 1.02 g ferumoxytol (2 × 510-mg injections) or 1.0 g iron sucrose administered as either a slow injection or infusion (10 doses for dialysis patients and 5 doses for nondialysis patients). Inclusion criteria included hemoglobin<11.0 g/dl, transferrin saturation<30%,

SUBMITTER: Macdougall IC 

PROVIDER: S-EPMC3974353 | biostudies-literature | 2014 Apr

REPOSITORIES: biostudies-literature